Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL156916 | 1.00 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL6877364 | 0.97 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL6001593 | 0.97 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1735796 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8107350 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10934305 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28325360 | 0.95 | ALDH1A1 (0.71) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8604353 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9728576 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8758555 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117990898-B | High-sensitivity and ultra-stable ELISA single-component color developing agent and stop solution | 禾旭(郑州)生物技术有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-117990898-A | High-sensitivity and ultra-stable ELISA single-component color developing agent and stop solution | 禾旭(郑州)生物技术有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-114790472-B | Fructosyl curcumin, preparation method and application | 上海龙殷生物科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-8114959-B2 | Increasing the shelf-life of bulk glucagon-like peptide by treating a solution or suspension with a pharmaceutical buffer (TRIS) and preservative (phenol) to raise the pH to 8.5-9.6; freeze drying; regeneration; injections/biological/ | NOVO NORDISK A/S (DK) | 2012-02-14 | — | — | US | claimed |
| EP-1633390-B1 | STABILIZED PHARMACEUTICAL GLP-1 PEPTIDE COMPOSITIONS | NOVO NORDISK AS (DK) | 2012-01-18 | — | — | EP | claimed |
| EP-1633391-B1 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | NOVO NORDISK AS (DK) | 2011-10-19 | — | — | EP | claimed |
| US-7632806-B2 | Stabilized pharmaceutical peptide compositions | NOVO NORDISK A/S (DK) | 2009-12-15 | — | — | US | claimed |
| US-7595293-B2 | Stable pharmaceutical compositions | NOVO NORDISK A/S (DK) | 2009-09-29 | — | — | US | claimed |
| US-20080318865-A1 | Increasing the shelf-life of bulk glucagon-like peptide by treating a solution or suspension with a pharmaceutical buffer (TRIS) and preservative (phenol) to raise the pH to 8.5-9.6; freeze drying; regeneration; injections/biological/ | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | claimed |
| US-20060183682-A1 | Stabilized pharmaceutical peptide compositions | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | claimed |
| US-20060178304-A1 | Stabilized pharmaceutical peptide compositions | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | US | claimed |
| US-20060084605-A1 | Stable pharmaceutical compositions | NOVO NORDISK A/S (DK) | 2006-04-20 | — | — | US | claimed |
| EP-1633390-A2 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | NOVO NORDISK A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| EP-1633391-A1 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | NOVO NORDISK A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004105790-A1 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | NOVO NORDISK A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105781-A2 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | NOVO NORDISK A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| WO-2004089985-A1 | STABLE PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-20240293317-A1 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-05 | — | — | US | disclosed |
| US-6096870-A | ISOLATION OF DAIRY PRODUCT POLYPEPTIDES; PROVIDING SAMPLE, PASSING SAMPLE THROUGH ION EXCHANGE RESIN, RECOVERING ELUATE, ELUTING IMMUNOGLOBULIN, LACTOGLOBULIN, LACTALBUMIN, SERUM ALBUMIN, LACTOFERRINS, AND LACTOPEROXIDASE | SEPRAGEN CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0712632-A1 | REMEDY FOR DISEASES CHARACTERIZED BY ABNORMAL ACCUMULATION OR ACTIVATION OF LEUKOCYTE | TORAY INDUSTRIES, INC. (JP) | 1996-05-22 | — | — | EP | disclosed |